THE BUDGET IMPACT OF DUORESP® SPIROMAX® COMPARED WITH COMMONLY PRESCRIBED DRY POWDER INHALERS FOR THE MANAGEMENT OF ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN ITALY- ESTIMATED IMPACT OF INHALATION TECHNIQUE

Author(s)

Torvinen S¹, Nicolai JL¹, Pulimeno S², di Nola L², Bruno GM³, Colombo GL⁴, Di Matteo S³, Valentino MC⁵, Lewis A⁶, Blackney M⁶, Burgio L², Plich A¹
¹Teva Pharmaceuticals Europe B.V., Amsterdam, The Netherlands, ²Teva Italia S.r.l., Assago (MI), Italy, ³S.A.V.E. Studi Analisi Valutazioni Economiche, Milano, Italy, ⁴University of Pavia, Milan, Italy, ⁵S.A.V.E. Studi - Health Economics & Outcomes Research, Milan, Italy, ⁶Covance Market Access, London, UK

Presentation Documents

PRS16-torvinen-s-sup-1-sup-nicolai-jl-sup-1-sup-strong-u-pulimeno-s-u-sup-2-sup-strong-di-nola-l-sup-2-sup-bruno-gm-sup-3-sup-colombo-gl-sup-4-sup-di-matteo-s-sup-3-sup-valentino-mc-sup-5-sup-lewis-a-sup-6-sup-blackney-m-sup-6-sup-burgio-l- ...

OBJECTIVES: DuoResp^® Spiromax^® (budesonide + formoterol fumarate dihydrate) is a fixed-dose combination (FDC) of inhaled corticosteroid (ICS) + long-acting beta agonist (LABA) in a novel dry powder inhaler (DPI). An economic model was developed to assess the budget impact of switching adult patients with persistent asthma and chronic obstructive pulmonary disease (COPD) from market-leading DPIs in the Italy – budesonide/formoterol Turbohaler® and fluticasone/salmeterol Diskus^® – to DuoResp^® Spiromax^®

Conference/Value in Health Info

2015-11, ISPOR Europe 2015, Milan, Italy

Value in Health, Vol. 18, No. 7 (November 2015)

Code

PRS16

Topic

Economic Evaluation

Topic Subcategory

Budget Impact Analysis

Disease

Respiratory-Related Disorders

Explore Related HEOR by Topic

Economic Evaluation

Presentation